Overexpression of disintegrin and metalloproteinase domain-containing protein 9 (ADAM9) in lung cancer reduced LDLR protein stability by promoting its proprotein convertase subtilisin/kexin type 9 (PCSK9)-mediated degradation, leading to decreased cholesterol uptake and triggering cholesterol biosynthesis. This evidence concerns the gene ADAM9 and lung cancer.